Proliferation, apoptosis, and survivin expression in a spectrum of melanocytic nevi

Journal of Cutaneous Pathology

Volumn 32, Issue 1, 2005, Pages 45-49

  Florell, Scott R ^a   Bowen, Anneli R ^a   Hanks, Adrianne N ^b   Murphy, Kelley J ^b   Grossman, Douglas ^a,b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLINE; SURVIVIN;

ADOLESCENT; ADULT; APOPTOSIS; ARTICLE; CELL COUNT; CELL PROLIFERATION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DYSPLASTIC NEVUS; HUMAN; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; JUVENILE MELANOMA; MELANOCYTIC NEVUS; NICK END LABELING; PROTEIN EXPRESSION;

ADOLESCENT; ADULT; APOPTOSIS; CELL PROLIFERATION; CHILD; CHILD, PRESCHOOL; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION; IN SITU NICK-END LABELING; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; NEVUS, PIGMENTED; RNA, MESSENGER; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 12944289477     PISSN: 03036987     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0303-6987.2005.00242.x     Document Type: Article

References (31)

1. Reed JC. Mechanisms of apoptosis. Am J Pathol 2000; 157: 1415.
2. Reed JC. Dysregulation of apoptosis in cancer. J Clin Oncol 1999; 17: 2941.
3. Cory S, Huang DC, Adams JM. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 2003; 22: 8590.
4. Liston P, Fong WG, Korneluk RG. The inhibitors of apoptosis: there is more to life than Bcl-2. Oncogene 2003; 22: 8568.
5. Morales-Ducret CR, van de Rijn M, Smoller BR. Bcl-2 expression in melanocytic nevi. Insights into the biology of dermal maturation. Arch Dermatol 1995; 131: 915.
6. Saenz-Santamaria MC, Reed JA, McNutt NS, Shea CR. Immunohistochemical expression of Bcl-2 in melanomas and intradermal nevi. J Cutan Pathol 1994; 21: 393.
7. Cerroni L, Soyer HP, Kerl H. Bcl-2 protein expression in cutaneous malignant melanoma and benign melanocytic nevi. Am J Dermatopathol 1995; 17: 7.
8. Grossman D, McNiff JM, Li F, Altieri DC. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol 1999; 113: 1076.
9. Bowen AR, Hanks AN, Allen SM, Alexander A, Diedrich MJ, Grossman D. Apoptosis regulators and responses in human melanocytic and keratinocytic cells. J Invest Dermatol 2003; 120: 48.
10. Sprecher E, Bergman R, Meilick A, et al. Apoptosis, Fas and Fas-ligand expression in melanocytic tumors. J Cutan Pathol 1999; 26: 72.
11. Penneys N, Seigfried E, Nahass G, Vogler C. Expression of proliferating cell nuclear antigen in Spitz nevus. J Am Acad Dermatol 1995; 32: 964.
12. Florell SR, Boucher KM, Holden JA, et al. Failure to detect differences in proliferation status of nevi from CDKN2A mutation carriers and non-carriers. J Invest Dermatol 2002; 118: 386.
13. Tu P, Miyauchi S, Miki Y. Proliferative activities in Spitz nevus compared with melanocytic nevus and malignant melanoma using expression of PCNA/cyclin and mitotic rate. Am J Dermatopathol 1993; 15: 311.
14. Li LX, Crotty KA, McCarthy SW, Palmer AA, Kril JJ. A zonal comparison of MIB1-Ki67 immunoreactivity in benign and malignant melanocytic lesions. Am J Dermatopathol 2000; 22: 489.
15. Niemann TH, Argenyi ZB. Immunohistochemical study of Spitz nevi and malignant melanoma with use of antibody to proliferating cell nuclear antigen. Am J Dermatopathol 1993; 15: 441.
16. Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 2003; 22: 8581.
17. Blanc-Brude OP, Mesri M, Wall NR, Plescia J, Dohi T, Altieri DC. Therapeutic targeting of the survivin pathway in cancer: initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis. Clin Cancer Res 2003; 9: 2683.
18. Banks DP, Plescia J, Altieri DC, et al. Survivin does not inhibit caspase-3 activity. Blood 2000; 96: 4002.
19. Liu T, Brouha B, Grossman D. Rapid induction of mitochondrial events and caspase-independent apoptosis in survivin-targeted melanoma cells. Oncogene 2004; 23: 39.
20. Li F, Ackermann EJ, Bennett CF, et al. Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat Cell Biol 1999; 1: 461.
21. Velculescu VE, Madden SL, Zhang L, et al. Analysis of human transcriptomes. Nat Genet 1999; 23: 387.
22. Grossman D, McNiff JM, Li F, Altieri DC. Expression of the apoptosis inhibitor, survivin, in nonmelanoma skin cancer and gene targeting in a keratinocyte cell line. Lab Invest 1999; 79: 1121.
23. Bowen AR, Hanks AN, Murphy KJ, Florell SR, Grossman D. Proliferation, apoptosis, and survivin expression in keratinocytic neoplasms and hyperplasias. Am J Dermatopathol 2004; 26: 177.
24. Li F, Ambrosini G, Chu EY, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998; 396: 580.
25. Bastian BC, Olshen AB, LeBoit PE, Pinkel D. Classifying melanocytic tumors based on DNA copy number changes. Am J Pathol 2003; 163: 1765.
26. Grossman D, Kim PJ, Schechner JS, Altieri DC. Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc Natl Acad Sci USA 2001; 98: 635.
27. Maize JC, Foster G. Age-related changes in melanocytic nevi. Clin Exp Dermatol 1979; 4: 49.
28. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972; 26: 239.
29. Burns FJ, Vanderlaan M, Sivak A, Albert RE. Regression kinetics of mouse skin papillomas. Cancer Res 1976; 36: 1422.
30. Alanko T, Rosenberg M, Saksela O. FGF expression allows nevus cells to survive in three-dimensional collagen gel under conditions that induce apoptosis in normal human melanocytes. J Invest Dermatol 1999; 113: 111.
31. Alanko T, Saksela O. Transforming growth factor beta-1 induces apoptosis in normal melanocytes but not in nevus cells grown in type I collagen gel. J Invest Dermatol 2000; 115: 286.